MEI Pharma Acquires Worldwide Rights To Investigational Drug Candidate PWT143

(RTTNews) - MEI Pharma Inc. (MEIP) announced that it has acquired exclusive worldwide rights to the investigational drug candidate PWT143 from Pathway Therapeutics, Inc., a privately held pharmaceutical company, for an undisclosed upfront payment with no future milestone or royalty obligations.

In pre-clinical studies, PWT143 has been found to be a potent and highly selective oral inhibitor of phosphatidylinositide 3-kinase (PI3K) delta, a molecular target that has been shown to play a critical role in the proliferation and survival of hematologic cancer cells.

MEI Pharma said it anticipates filing an Investigational New Drug or IND application for PWT143 by the end of 2014.